# EDGAR Filing Document

**Accession Number:** 0001949257
**File Stem:** 0001213900-25-087432
**Filing Date:** 2025-9
**Character Count:** 8853
**Document Hash:** f97e594cd5e63a0c79aef6c8ba090fff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-087432.hdr.sgml**: 20250915

**ACCESSION NUMBER**: 0001213900-25-087432

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250915

**FILED AS OF DATE**: 20250915

**DATE AS OF CHANGE**: 20250915

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Radiopharm Theranostics Ltd
- **CENTRAL INDEX KEY:** 0001949257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41621
- **FILM NUMBER:** 251313245

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 62 LYGON STREET
- **CITY:** CARLTON VIC
- **PROVINCE COUNTRY:** C3
- **ZIP:** 3053
- **BUSINESS PHONE:** 61 3 9824 5254

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 62 LYGON STREET
- **CITY:** CARLTON VIC
- **PROVINCE COUNTRY:** C3
- **ZIP:** 3053

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of September 2025

Commission File Number: 001-41621

**<u>RADIOPHARM THERANOSTICS LIMITED</u>**

(Name of Registrant)

**<u>Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia</u>**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

**RADIOPHARM THERANOSTICS LIMITED**

**<u>EXPLANATORY NOTE</u>**

Radiopharm Theranostics Limited (the "Company") published one announcement (the "Public Notice") to the Australian Securities Exchange on September 15, 2025 titled:

- "Pivalate (Brain Mets) key opinion leader webinar"

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit** <br> **Number** | **Description** |
| 99.1 | [Pivalate (Brain Mets) key opinion leader webinar](ea025733301ex99-1_radio.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **RADIOPHARM THERANOSTICS LIMITED** | **RADIOPHARM THERANOSTICS LIMITED** |
| Date: September 15, 2025 | By: | /s/ Phillip Hains |
|  |  | Phillip Hains |
|  |  | Company Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| **ASX ANNOUNCEMENT<br> 15 SEPTEMBER 2025** | ![](ex99-1_001.jpg) |

---

**RADIOPHARM TO HOST PIVALATE (BRAIN METS) KEY OPINION LEADER WEBINAR** 

**Sydney, Australia – 15 September 2025** – Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to advise that it is hosting a key opinion leader webinar to discuss Pivalate and the detection of relapsed brain metastases from solid tumors.

**WEBINAR DETAILS**

**10:30am AEST – Thursday 25 September**

**Click here to register**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**TIME** | &nbsp;&nbsp;**TOPICS** | &nbsp;&nbsp;**SPEAKERS** |
| &nbsp;&nbsp;10:30-10:35am | &nbsp;&nbsp;Webinar Introduction | &nbsp;&nbsp;Dr Dimitris Voliotis (RAD) |
| &nbsp;&nbsp;10:35-10:50am | &nbsp;&nbsp;Challenges, unmet needs for the radiographic detection of relapsed brain metastases from solid tumors and consequences for therapeutic approaches | &nbsp;&nbsp;Dr Ramji Rajendran (Alexian Brothers Medical Center, Chicago, IL) |
| &nbsp;&nbsp;10:50-11:00am | &nbsp;&nbsp;Background of Pivalate (18F-FPIA) as an imaging agent in patients with brain metastases from solid tumors | &nbsp;&nbsp;Dr Dimitris Voliotis (RAD) |
| &nbsp;&nbsp;11:00-11:10am | &nbsp;&nbsp;Pivalate's path to approval and its clinical and commercial potential | &nbsp;&nbsp;Riccardo Canevari (RAD) |
| &nbsp;&nbsp;11:10-11:25am | &nbsp;&nbsp;Q&A and closing remarks | &nbsp;&nbsp;Dr Dimitris Voliotis (RAD) |

---

F18-Pivalate is a novel radiotracer being developed for the detection, characterisation, and progression monitoring of glioblastoma and relapsed brain metastases. It works by targeting fatty acid synthase, which is selectively overexpressed by tumors but not in normal brain cells. This gives Pivalate a unique mechanism of action and a potentially transformational approach in the imaging and monitoring of brain metastases. Approximately 20-40% of patients with cancer will develop metastatic cancer to the brain during the course of their illness, making more accurate detection methods essential. Currently available technologies, such as FDG PET and MRI, have significant limitations in their ability to differentiate between necrosis, inflammation and true recurrence. F18-Pivalate has been designed to overcome these limitations, offering a more precise and reliable tool for clinicians.

**Dr Ramji Rajendran**

Dr Ramji Rajendran is a highly skilled and compassionate radiation oncologist with a unique background in both clinical practice and research. He completed his MD and PhD in a combined program at the University of Illinois at Urbana-Champaign, where his doctoral research focused on molecular mechanisms and cell biology of hormone-dependent cancers such as breast and prostate cancer.

After completing his residency at the prestigious Hospital of the University of Pennsylvania in Philadelphia, Dr Rajendran has dedicated his career to advancing cancer treatment through radiation oncology. He currently serves as the Medical Director of the Department of Radiation Oncology and Illinois Gamma Knife Center at Ascension Alexian Brothers Medical Center.

Dr Rajendran's expertise spans a wide range of advanced radiation therapy techniques, including IMRT, SBRT, and gamma knife radiosurgery. His research contributions in prostate organ motion, proton radiation therapy, and radiation therapy for breast and thoracic tumors have been presented nationally and internationally.

**Radiopharm Theranostics Limited<br> Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia<br> ABN: 57 647 877 889**

---

| | |
|:---|:---|
| **ASX ANNOUNCEMENT<br> 15 SEPTEMBER 2025** | ![](ex99-1_001.jpg) |

---

**About Radiopharm Theranostics**

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.

**Authorised on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.**

**For more information:**

**Investors:**

Riccardo Canevari<br> CEO & Managing Director<br> P: +1 862 309 0293<br> E: rc@radiopharmtheranostics.com

Anne Marie Fields<br> Precision AQ<br> (Formerly Stern IR)<br> E: annemarie.fields@precisionaq.com

**Media:**

Matt Wright<br> NWR Communications<br> P: +61 451 896 420<br> E: matt@nwrcommunications.com.au

**Follow Radiopharm Theranostics:** 

Website – https://radiopharmtheranostics.com/<br> Twitter – https://twitter.com/TeamRadiopharm<br> Linked In – https://www.linkedin.com/company/radiopharm-theranostics/<br> InvestorHub – https://investorhub.radiopharmtheranostics.com/

**Radiopharm Theranostics Limited<br> Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia<br> ABN: 57 647 877 889**